A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
This study looks at a new targeted medicine called repotrectinib for children, teenagers, and young adults up to 25 years old. It is designed for people with advanced solid tumours, brain tumours, or lymphomas that carry specific faulty genes called ROS1 or NTRK. These gene faults act like broken switches, telling cancer cells to keep growing. The trial has two main parts. The first part works out the safest and most comfortable dose for children under 12. The second part tests how well the drug shrinks tumours in people aged 12 to 25, as well as younger children once their best dose is confirmed. Repotrectinib is taken by mouth as a pill or liquid. Taking part involves taking the medicine every day, coming to regular hospital check-ups, and having scans to see if the treatment is helping.
At a glance
What is this study about?
Some cancers are driven by specific changes in their genetic code. In this trial, researchers are focusing on changes involving genes called ROS1, NTRK, and ALK. When these genes fuse with other genes, they can make cancer cells grow and spread quickly. Repotrectinib is a type of targeted therapy designed to block the signals these faulty genes produce, aiming to slow down or stop the cancer from growing.
Because this is an early-stage study, doctors are carrying it out in two phases. Phase 1 focuses on younger children under 12 years old. Its goal is to find the right dose that works against the tumour without causing too many uncomfortable side effects. Phase 2 includes teenagers and young adults aged 12 to 25 (and later, younger children), looking closely at whether the medicine actually shrinks tumours or keeps them stable.
This trial matters because children and young people with advanced or recurring cancers often have very limited treatment choices. Finding targeted medicines that can be taken by mouth could offer a kinder and more effective option when standard therapies such as chemotherapy or radiotherapy have stopped working.
Key takeaways
- Tests a targeted oral medicine called repotrectinib for children and young adults aged 0 to 25.
- Aimed at advanced solid tumours, brain tumours, or lymphomas with ROS1 or NTRK gene changes.
- Designed for patients who have already tried standard treatments or have no other curative options.
- The study checks the safest dose for young children and measures how well the drug shrinks tumours.
- Taking part is voluntary, and you can withdraw at any time without losing standard medical support.
Who may be eligible?
This study is open to children, teenagers, and young adults up to the age of 25 who have an advanced solid tumour, a primary brain tumour, or a type of lymphoma. To be considered, testing on a tumour sample must show a confirmed change in the ROS1 or NTRK genes. It is meant for patients whose cancer has continued to grow after standard treatments, or for whom no standard curative therapy exists.
Participants must have tumour areas that can be measured on scans so doctors can monitor any changes. It is also important that patients are reasonably active (able to be out of bed for at least half the day) and have working liver, kidney, and bone marrow function. If someone has a brain tumour, their condition must be stable.
You cannot join this study if your cancer is neuroblastoma that is only present in the bone marrow, or if you are still recovering from severe side effects caused by recent cancer treatments.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- The patient is aged 25 or younger.
- The patient has an advanced solid tumour, brain tumour, or lymphoma.
- A lab test has confirmed a ROS1 or NTRK gene change in the tumour.
- The tumour can be measured on a CT or MRI scan.
- The patient is well enough to be up and about for at least half of the day.
What does participation involve?
If you or your child join this study, the trial medicine (repotrectinib) will be taken by mouth as capsules or a liquid once or twice every day. You can take this medicine at home, but you will need to keep a simple diary to record each dose.
You will need to visit the hospital regularly, especially during the first few weeks, so the medical team can keep a close eye on your health. These visits will include physical examinations, blood tests, heart checks (such as ECGs), and regular imaging scans (like MRI or CT scans) to check on the tumour.
Participants can usually remain on the study for as long as the medicine helps to control the cancer without causing unacceptable side effects. Taking part is entirely voluntary, and you can decide to stop the treatment at any time.
Potential risks and benefits
Locations (68)
- Children's Hospital Los AngelesVerified postcodeLos Angeles, United States· Recruiting
- University of California at Los AngelesVerified postcodeLos Angeles, United States· Recruiting
- Children's Hospital Colorado - Anschutz Medical CampusVerified postcodeAurora, United States· Recruiting
- Local Institution - 2105Verified postcodeOrlando, United States· Completed
- Local Institution - 2120Verified postcodeOrlando, United States· Completed
- Children's Healthcare of Atlanta - Egleston HospitalVerified postcodeAtlanta, United States· Recruiting
- Maine Medical CenterVerified postcodeScarborough, United States· Recruiting
- Dana Farber Cancer Institute.Verified postcodeBoston, United States· Recruiting
- Washington University School of Medicine in St. LouisVerified postcodeSt Louis, United States· Recruiting
- Local Institution - 2110Verified postcodeNew Brunswick, United States· Completed
- Local Institution - 2102Verified postcodeNew York, United States· Completed
- Levine Children's Hospital- Pediatric Neuro-OncologyVerified postcodeCharlotte, United States· Recruiting
Common questions
How is the trial medicine given?
Repotrectinib is taken by mouth as a pill or a liquid, meaning it can be taken at home rather than requiring an intravenous drip in the hospital.
How do I know if my tumour has the right gene change?
Your hospital team can test a small sample of tumour tissue that was removed during a previous biopsy or operation to see if it carries the ROS1 or NTRK gene changes.
Will taking part cost anything?
No. The study drug and any extra tests required by the clinical trial are provided free of charge. Some trials also help with travel expenses to and from the hospital.
Can I leave the trial if I change my mind?
Yes. You can leave the study at any time and for any reason. Your normal medical care and relationship with your doctors will not be affected.
What happens if the cancer continues to grow?
If scans show that the tumour is growing or if the treatment is causing difficult side effects, your doctor will discuss stopping the trial drug and looking at other care options.
How to find out more
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.